KSA
ALXN

Ken Stern & Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Ken Stern & Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$306K Hold
2,200
– – 0.13% 100
2018
Q2 		$273K Hold
2,200
– – 0.13% 101
2018
Q1 		$245K Hold
2,200
– – 0.11% 107
2017
Q4 		$263K Sell
2,200
-500
-19% -$60.9K 0.11% 98
2017
Q3 		$380K Hold
2,700
– – 0.17% 68
2017
Q2 		$330K Sell
2,700
-500
-16% -$58.2K 0.15% 78
2017
Q1 		$409K Hold
3,200
– – 0.19% 67
2016
Q4 		$392K Buy
+3,200
New +$392K 0.2% 73

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ken Stern & Associates's ALXN Position: Q3 2018 in Review

Ken Stern & Associates held its Alexion Pharmaceuticals (ALXN) position steady in Q3 2018 at 2,200 shares worth $306K. The position accounts for 0.13% of the portfolio, ranked #100.

Ken Stern & Associates first reported a position in ALXN in Q4 2016 and has held it in 8 quarters since. The position peaked at $409K in Q1 2017. 584 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

  • Ken Stern & Associates held 2,200 shares of Alexion Pharmaceuticals worth $306K as of Q3 2018.
  • Ken Stern & Associates left its Alexion Pharmaceuticals share count unchanged in Q3 2018.
  • Alexion Pharmaceuticals made up 0.13% of Ken Stern & Associates's portfolio in Q3 2018, its #100 holding.
  • Ken Stern & Associates first reported a position in Alexion Pharmaceuticals in Q4 2016 and has held it in 8 quarters since.
  • Ken Stern & Associates's Alexion Pharmaceuticals position peaked at $409K in Q1 2017.
  • 584 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Ken Stern & Associates's 13F filing for Q3 2018, filed 13 Nov 2018.